Entwicklung der Behandlungslandschaft beim multiplen Myelom durch T-Zell-Therapien und Herausforderungen in der Studiengestaltung

Die Behandlungslandschaft beim multiplen Myelom undergo significant changes as T-cell engaging therapies, including bispecific antibodies and CAR T-cell treatments, reshape care and clinical trial design. These advances are shifting the disease toward a chronic condition with potential treatment breaks, while creating new challenges for managing side effects and designing adaptable clinical trials.

Continuous therapy has been a common approach, but with the availability of bispecifics and CAR T therapies, there may be an end to treatment for patients, allowing long breaks from therapy. This shift has also changed the toxicity profile for patients. Traditional quad- and triplet-based regimens are typically associated with fatigue, neuropathy, and gastrointestinal side effects. T-cell engaging therapies like bispecific antibodies and CAR T-cell therapy are associated with acute events such as cytokine release syndrome, neurotoxicity, and ongoing infectious complications. Depending on the type of bispecific antibody, there can also be skin, hair, and nail toxicities that require patient education.

For relapsed and refractory myeloma patients, chronic pain is an ongoing issue that can persist over time. Managing fatigue and peripheral neuropathy remains important. Financial toxicity is also a critical consideration, and understanding patients' social, job, family, and community obligations helps guide treatment decisions.

Multiple myeloma clinical trials are evolving faster than traditional trial design frameworks can accommodate. As CAR-T therapies, bispecific antibodies, and next-generation immune targets rapidly reshape the standard of care, sponsors face increasing complexity in selecting appropriate comparator arms, aligning regulatory strategy, and designing sustainable oncology clinical trials. Comparator selection in multiple myeloma has become a strategic determinant of early-phase and late-phase oncology drug development success.

Challenges include heterogeneous real-world treatment patterns, shifting standard of care pathways, and evolving regulatory expectations. Emerging strategies involve integrating regulatory intelligence with feasibility assessments, designing adaptive oncology trials aligned with ICH E6(R3) guidance, and incorporating modular protocol architecture, adaptive randomization, and external control strategies. For emerging and mid-size biotechs entering the multiple myeloma space, an integrated clinical development strategy, regulatory insight, and operational intelligence can reduce protocol amendments, preserve interpretability at readout, and accelerate oncology drug development timelines.